RxDoctor Payments DataLook up a doctor →

Michael Becker, MD

Neurology · Lacombe, LANPI 1992703920

Payments from drug & device makers

$21,201in general payments, 2019–2025

Across 1,319 payments — averaging $16.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$2K
  • AbbVie$2K
  • Biogen$1K
  • UCB, Inc.$1K
  • Grifols USA, LLC$1K
  • Amgen$997
  • plus $13K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Acadia Pharmaceuticals Inc147$1,970
AbbVie(2 entities)133$1,650
Biogen92$1,401
UCB, Inc.68$1,188
Grifols USA, LLC63$1,067
Amgen(2 entities)61$997
CSL Behring30$670
SK Life Science, Inc.30$653
Lundbeck LLC34$640
Lilly USA, LLC41$592
Sanofi32$561
Novartis42$555
Sunovion Pharmaceuticals Inc.44$554
Pfizer34$531
Argenx US, Inc.22$522
Acorda Therapeutics, Inc26$485
MDD US Operations, LLC20$425
Eisai Inc.21$413
Neurocrine Biosciences, Inc.21$387
Teva Pharmaceuticals USA, Inc.34$370
Bristol Myers Squibb23$352
AstraZeneca(2 entities)20$332
Kyowa Kirin, Inc.17$308
Biohaven Pharmaceuticals, Inc.16$298
EMD Serono, Inc.21$295
Genentech USA, Inc.18$292
Supernus Pharmaceuticals, Inc.10$278
Boston Scientific14$246
Jazz Pharmaceuticals Inc.16$246
Otsuka America Pharmaceutical, Inc.12$209
Merz Pharmaceuticals, LLC11$203
GE HealthCare9$193
Johnson & Johnson(2 entities)12$181
Sumitomo Pharma America, Inc.18$173
Arbor Pharmaceuticals, Inc.12$164
Nevro Corp.2$151
Adamas Pharmaceuticals, Inc.8$122
Alnylam Pharmaceuticals Inc.6$115
Tanabe Pharma America, Inc.6$105
Takeda Pharmaceuticals U.S.A., Inc.5$104
Saluda Medical Americas, Inc.1$96
Scilex Pharmaceuticals Inc.6$94
Upsher-smith Laboratories LLC7$94
GRT US Holding, Inc.5$83
ANI Pharmaceuticals, Inc.4$80
Abbott4$64
Neurelis, Inc.3$61
Catalyst Pharmaceuticals, Inc.4$59
Tersera Therapeutics LLC3$43
Promius Pharma LLC2$43
Assertio Therapeutics, Inc.3$42
Biohaven Pharmaceutical Holding Company Ltd.3$41
Almatica Pharma LLC3$40
Azurity Pharmaceuticals, Inc.2$36
Ipsen Biopharmaceuticals, Inc1$33
Avanir Pharmaceuticals, Inc.2$29
Axsome Therapeutics, Inc.1$28
Strongbridge US Inc.2$25
Xeris Pharmaceuticals, Inc.1$24
Sanofi-aventis U.S. LLC1$21

How this compares

$21,201 in reported general payments places this provider in the 80th percentile of 225 neurology providers in Louisiana.

See all neurology providers in Louisiana →

Medicare billing

Part B allowed, 2024
$169,087
Medicare patients
405
Services billed
1,604

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Lacombe

See the full list for Louisiana →

Where these figures come from

Is this you, or does something look wrong? →